Tango Therapeutics, Inc.
Clinical trials sponsored by Tango Therapeutics, Inc., explained in plain language.
Tango Therapeutics, Inc.
TNGX
NASDAQ
A clinical-stage biotechnology company developing targeted cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for hard-to-treat cancers: experimental combo targets STK11 mutation Results expected Sep 2026 (estimated)
- New drug targets Hard-to-Treat cancers with missing gene Results expected Mar 2027 (estimated) May already have reported ↗
- New hope for hard-to-treat cancers: targeted combo trial opens Results expected Jun 2027 (estimated)
- New pill targets Hard-to-Treat cancers with missing gene Results expected Jun 2027 (estimated)